Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 7, 2017

Zimmer Biomet to launch new procedure to repair BMLs

US-based healthcare firm Zimmer Biomet Holdings is set to launch its Subchondroplasty (SCP) Procedure across multiple countries, for the treatment of bone marrow lesions (BMLs).

US-based healthcare firm Zimmer Biomet Holdings is set to launch its Subchondroplasty (SCP) Procedure across multiple countries, for the treatment of bone marrow lesions (BMLs).

The firm has secured CE mark approval for the procedure, enabling distribution in the European Union (EU) and other countries that recognise the CE mark, along with approval for distribution in Canada, Singapore, Malaysia and Hong Kong.

The SCP Procedure is a minimally invasive outpatient intervention designed to repair the defects caused due to subchondral (BMLs), by filling them with a porous injectable calcium phosphate (CaP) called AccuFill Bone Substitute Material.

"The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon."

The healthy bone then replaces the bone substitute, which is slowly resorbed.

The new procedure is performed with arthroscopy to enable visualisation and to treat findings inside the joint, while the defect might sometimes require an open or mini-open procedure to facilitate access.

Zimmer Biomet Group president David Nolan said: "The international release of the Subchondroplasty Procedure is a major milestone for our company and for patients with chronic bone marrow lesions.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

"The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon.

"We are eager to begin our international commercial launch."

Diagnosed with an MRI and physical exam, BMLs may develop due to stress fractures or micro-fractures of the bone adjacent to the joint, resulting in cartilage degeneration, limited function, pain and joint deterioration.  .

With 36 patents and eight trademarks, the SCP procedure can be used for bone defects of the knee, foot, ankle and hip.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU